Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Views On Emerging Markets: JP Morgan Healthcare Conference (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. In this feature, PharmAsia News takes a closer look.

You may also be interested in...



In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India

WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts

Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local

Russia Premier Vladimir Putin has said he wants multinational pharmaceutical companies to manufacture drugs in Russia and support development of the local industry as part of a $4 billion government initiative to reform the Russia healthcare market by 2020. So perhaps it is not too surprising that both Novartis AG and AstraZeneca PLC chose to re-emphasize their commitments to Russia by each issuing press releases June 16 to coincide with the kickoff of the St. Petersburg International Economic Forum

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel